July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Intravitreal Autologous Bone Marrow CD34+ Cell Therapy for Retinal Vein Occlusion: phase I/II clinical trial
Author Affiliations & Notes
  • Susanna S Park
    Ophthalmology & Vision Science, Univ of California Davis Eye Ctr, Sacramento, California, United States
  • Footnotes
    Commercial Relationships   Susanna Park, Allergan (F), Novartis (F), Roche (F)
  • Footnotes
    Support  NIH Grants UG1 EY026876 & UG1 EY028517
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3905. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Susanna S Park; Intravitreal Autologous Bone Marrow CD34+ Cell Therapy for Retinal Vein Occlusion: phase I/II clinical trial. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3905. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : It is well accepted that CD34+ cells are endogenous repair cells that are mobilized in response to tissue ischemia for repair. The CD34+ cells include endothelial progenitor cells as well as hematopoietic stem cells. They play an active role in tissue revascularization. Preclinical studies show that these cells home into the damaged retinal vasculature following intravitreal administration and integrate long-term without ocular or systemic adverse effects. Study findings support regenerative effects of these CD34+ cells via direct vascular engraftment and via paracrine mechanisms. A phase 1 clinical trial has been conducted at the study center showing that the autologous intravitreal CD34+ cell therapy is feasible and without major safety concerns. Among eyes treated with persistent vision loss from various retinal conditions, the eye with retinal vein occlusion had the most dramatic improvement following this cell therapy. Thus, an expanded phase I/II study will be conducted to further explore this autologous cell therapy for persistent vision loss associated with retinal vein occlusion.
A phase I/II randomized, prospective, double-blinded, sham controlled cross-over study is planned exploring the safety and potential efficacy of intravitreal administration of autologous CD34+ cell isolated from bone marrow as treatment for vision loss associated with retinal vein occlusion. This single-center study will be conducted at the University of California Davis. Emmes Corporation will be the coordinating center. The National Eye Institute is the study sponsor. The study is being conducted under an IND cleared by the Food and Drug Administration. This five-year study will enroll up to twenty eyes from twenty subjects with persistent vision loss associated with retinal vein occlusion. Each subject will be randomized 1:1 to either prompt treatment with autologous CD34+ cells or sham injection with deferred CD34+ cell treatment at 6 months. Each study subject will be followed for 2 years. The primary endpoint of this study will be the incidence and severity of ocular and systemic side-effects associated with the study treatment. The secondary endpoint of this study will be functional and morphologic changes following cell therapy as accessed by clinical examination and various diagnostic modalities.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.